Regeneron (REGN), Sanofi (SNY)Announce Two Dupilumab Phase 3s Met Primary Endpoint in Atopic Dermatitis
Tweet Send to a Friend
Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) and Sanofi (NYSE: SNY) announced that two placebo-controlled Phase 3 studies evaluating investigational dupilumab in ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
